Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

Item
http://www.wikidata.org/entity/Q33926222
BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case ReportEfficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Adherence to BCR-ABL inhibitors: issues for CML therapy.The expanding role of nilotinib in chronic myeloid leukemia.Evolution of therapies for chronic myelogenous leukemia.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.Dasatinib dose management for the treatment of chronic myeloid leukemia.Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
P2860

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

Item
http://www.wikidata.org/entity/Q33926222
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@ast
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@en
type
label
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@ast
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@en
prefLabel
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@ast
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Clinical impact of dose reduct ...... ith chronic myeloid leukaemia.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2141.2010.08245.X
P407
P433
P478
P50
P577
P5875
P698
P921
P932